Actavis Realigns Business To Increase Efficiency
This article was originally published in The Pink Sheet Daily
The global specialty brand and generics company is simplifying its structure and combining units to make communication and decisions across the business more effective as it strives to grow organically.
You may also be interested in...
Actavis Divests In China But Looking For Acquisition; CEO Says Pfizer’s Established Products Division Possible
Actavis is pulling out of China because its business there is too small and complicated considering the investment of time and capital that could be better spent elsewhere But it could re-enter via a sizeable acquisition, such as Pfizer’s Established Products division.
The traditionally generic-heavy company now has an expanded global presence and a growing branded business to go with its new name.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.